Stem cells from bone marrow are being investigated as possible treatments for Multiple Sclerosis

5trialstaggedasMultipleSclerosis

• Stem Cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)Location: UK
  Overview:This trial is investigating the effect of the patient’s own mesenchymal stem cells in multiple sclerosis (MS). The trial is being conducted by the Imperial College Hospital in London expects to enrol 13 patients between January 2013 and July 2015. Bone marrow stem cells will be harvested from all the participants and expanded in the laboratory over 52 days. Participants will be randomly assigned into treatment or control groups. Those in the control group will receive standard treatment and a placebo injection, whilst those in the treatment group will receive their own expanded cells. Neither the patients, nor the doctors will know which group they are in. Participants will be monitored for complications, as well changes in the number of sclerotic lesions in the brain. After 24 weeks patients in the control group will receive their expanded stem cells and both groups monitored again as in the first 24 weeks.

  Link to Clinical Registry

  Trial Design:Safety and Efficacy Study

  Status:Open – Recruiting

  Stem Cell:Adult Bone Marrow Stem Cells
• Own Mesenchymal Stem Cells for Multiple Sclerosis PatientsLocation: Denmark
  Overview:This trial aims is to determine the effect of the patient’s own MSCs on cerebral inflammation in Multiple Sclerosis. The trial is being conducted by the Danish Blood Bank in conjunction with the Danish Multiple Sclerosis Society. The trial commenced in June 2012 and seeks to enrol 25 patients. Participants will be randomly divided into two groups. One group will receive mesenchymal stem cells, from their own bone marrow, intravenously (initial experimental group). This group will be monitored for 24 weeks in which MRI scans will be used to monitor lesions. The remaining subjects will receive the conventional therapy for Multiple Sclerosis and then after 24 weeks, they receive a similar mesenchymal stem cell infusion and monitored by MRI for a further 24 weeks. During this time the initial experimental group will receive only conventional therapy. This is a randomised, controlled, double blinded, and double group crossover clinical trial. No end date has been set for this trial.

  Link to Clinical Registry

  Trial Design:Therapeutic intervention

  Status:Open – Recruiting

  Stem Cell:Adult Bone Marrow Stem Cells
• Mesenchymal Stem Cells for Multiple SclerosisLocation: Sweden
  Overview:This trial aims to investigate the effect of stem cells from the patient’s own bone marrow in treating multiple sclerosis. The trial is being conducted by the Karolinska Institute and the Karolinska University Hospital Solna in Stockholm and proposes to recruit 15 subjects between February 2013 and December 2015. Participants will be divided into two groups. The first group will receive an injection of their own bone marrow stem cells at the beginning of the trial. The second group will receive the injection of their own stem cells 24 weeks later. All participants will be monitored for complications and changes in clinical condition at our-week intervals for 48 weeks.

  Link to Clinical Registry

  Trial Design:Safety and Efficacy Study

  Status:Open – Recruiting

  Stem Cell:Adult Bone Marrow Stem Cells
• Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed with Multiple SclerosisLocation: Spain
  Overview:This trial aims to evaluate the use of stem cells from the patient’s own bone marrow in treatment of Multiple Sclerosis. The trial is being sponsored by Fundación Pública Andaluza Progreso y Salud and is being conducted at three University hospitals in Spain. They propose to recruit 30 patients between May 2012 and November 2014. All participants will have bone marrow stem cells harvested prior to commencement of the trial. Being a crossover study the subjects will be divided into two groups. The first group will receive the stem cell injection on the first day, while the second group will receive a placebo infusion. After 180 days, the second group will receive the stem cell injection and the first group a placebo injection. All participants will be monitored for complications following the transfusion and changes in clinical condition for one year.

  Link to Clinical Registry

  Trial Design:Safety and Efficacy Study

  Status:Open – Recruiting

  Stem Cell:Adult Bone Marrow Stem Cells
• A Single Centre Phase II Study Of Haematopoietic Stem Cell Transplantation for Severe Auto-Immune DiseasesLocation: Australia
  Overview:This trial is evaluating the use of combining immunosuppression and the patient’s bone marrow stem cells in patients with serious diseases of the immune system which have not responded to conventional treatments. The trial is being conducted at St Vincent’s Hospital in Sydney and began recruiting patients in March 2011 with plans to recruit 30 subjects by December 2015. The conditions being investigated in the trial include Scleroderma, Multiple Sclerosis, Systemic Lupus Erythematosus (SLE), vasculitis, Crohn’s disease and Behcet’s disease. Participants will be given Granulocyte Colony Stimulating Factor (G-CSF) to stimulate the bone marrow into releasing stem cells, which will then be harvested from the blood of each participant. The patients will then undergo a course of intensive chemotherapy and/or immunotherapy depending on the individual condition after which they will receive an infusion of their own stem cells. Participants will be monitored for complications and assessed for changes in their clinical condition.

  Link to Clinical Registry

  Trial Design:Observational Study

  Status:Open – Recruiting

  Stem Cell:Adult Bone Marrow Stem Cells

Article Source found here